 |
PDBsum entry 1uj3
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system/blood clotting
|
PDB id
|
|
|
|
1uj3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
214 a.a.
|
 |
|
|
|
|
|
|
|
217 a.a.
|
 |
|
|
|
|
|
|
|
205 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structure of a humanized FAB fragment of anti-Tissue-Factor antibody in complex with tissue factor.
|
 |
|
Authors
|
 |
U.Ohto,
R.Mizutani,
M.Nakamura,
H.Adachi,
Y.Satow.
|
 |
|
Ref.
|
 |
J Synchrotron Radiat, 2004,
11,
105-108.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Tissue factor (TF) is a membrane-anchored protein that initiates the extrinsic
cascade of blood coagulation. TF forms a complex with serine protease Factor
VIIa, and then activates Factor X zymogen to Factor Xa, leading to the blood
coagulation. Humanized anti-TF antibody hATR-5 strongly inhibits TF-initiated
blood coagulation, and is of potential use for various thrombotic diseases. The
Fab fragment of antibody hATR-5 is obtained for crystallization. The crystal
structure of the complex of the Fab with extracellular domains of human TF was
determined with the molecular replacement method, and refined to an R factor of
0.196 at 2.1 A resolution. All the complementarity-determining regions (CDRs) of
the Fab are involved in interaction with the C-terminal-side extracellular
domain of TF through 19 hydrogen bonds. The interface between the Fab and TF
molecules contains 15 water molecules, and yields buried surface areas as wide
as 2000 A2. The TF surface in the interface is possibly involved in the
activation of Factor X, by forming a transient ternary complex of Factor
X-TF-Factor VIIa. Electrostatic interactions are predominantly observed between
the heavy-chain CDRs and TF. These hydrogen-bonding and electrostatic
interactions together with the wide buried areas contribute to the high affinity
of the antibody toward TF, leading to the effective inhibition of the
TF-initiated blood coagulation.
|
 |
|
|
|
|
 |